10-Q: Reviva Pharma Secures $9.7M, Faces Nasdaq Delisting Risk

Reviva Pharmaceuticals Holdings, Inc. reported a reduced net loss and successful clinical trial completions for brilaroxazine, but raised $9.7 million in new capital while facing substantial doubt about its ability to continue as a going concern and Nasdaq delisting threats.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $12.5 million from $15.3 million in the prior year.
• Research and development expenses decreased by 31.1% to $7.8 million for the six months ended June 30, 2025, compared to $11.4 million in the same period last year.
• Cash and cash equivalents stood at $10.4 million as of June 30, 2025, down from $13.5 million at December 31, 2024.
• The company reported a working capital deficit of $1.3 million and an accumulated deficit of $176.8 million as of June 30, 2025.
• Successfully completed the Phase 3 RECOVER open-label extension (OLE) 1-year study for brilaroxazine in schizophrenia, showing sustained efficacy and tolerability.
• Raised approximately $9.7 million in net proceeds from an At-The-Market (ATM) offering and a public offering of common stock and warrants in Q2 2025.
• Received notices from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement (May 13, 2025) and the $35 million Market Value of Listed Securities (MVLS) requirement (August 8, 2025).
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting.

Sentiment

Score: 4

Explanation: While positive clinical trial results for brilaroxazine and a reduced net loss are favorable, the company faces severe liquidity issues, a "going concern" warning, and imminent Nasdaq delisting threats. The need for continuous capital raises and identified material weaknesses in internal controls add significant uncertainty and risk, overshadowing the clinical progress.

Positives

• Net loss for the six months ended June 30, 2025, improved to $12.5 million from $15.3 million in the prior year.
• Research and development expenses decreased by 31.1% to $7.8 million for the six months ended June 30, 2025, compared to $11.4 million in the same period last year, primarily due to the OLE trial proceeding toward completion.
• Successfully completed the Phase 3 RECOVER open-label extension (OLE) 1-year study for brilaroxazine, demonstrating robust broad-spectrum efficacy sustained over one year and general tolerability in schizophrenia patients.
• Positive topline results from the pivotal Phase 3 RECOVER-1 trial for brilaroxazine in acute schizophrenia were announced in October 2023, meeting the primary endpoint at the 50 mg dose.
• The company believes it has met the statutory clinical data requirement for NDA submission for brilaroxazine based on existing data (RECOVER-1, OLE, Phase 2 REFRESH).
• Secured approximately $9.7 million in net proceeds from recent equity offerings (ATM and public offering) to fund ongoing operations and development.
• Maintains a strong intellectual property portfolio with 70 granted patents and 12 pending applications for brilaroxazine and RP1208.

Negatives

• The company has incurred losses since inception and reported an accumulated deficit of $176.8 million as of June 30, 2025.
• Working capital deteriorated significantly, moving from a surplus of $81,861 at December 31, 2024, to a deficit of $1.3 million at June 30, 2025.
• Cash and cash equivalents decreased by $3.1 million to $10.4 million as of June 30, 2025, from $13.5 million at December 31, 2024.
• Current cash on hand is not sufficient to satisfy operating cash needs for the next 12 months, leading to substantial doubt about the company's ability to continue as a going concern.
• Received notices from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement and the $35 million Market Value of Listed Securities (MVLS) requirement, risking delisting.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to identified material weaknesses in internal control over financial reporting.
• Total stockholders' equity moved into a deficit of $(459,147) as of June 30, 2025, from a surplus of $812,572 at December 31, 2024.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern for a period of one year after the financial statements are issued, requiring additional funding.
• Risk of delisting from The Nasdaq Capital Market due to non-compliance with the $1.00 minimum bid price requirement (deadline November 10, 2025) and the $35 million Market Value of Listed Securities (MVLS) requirement (deadline February 4, 2026).
• Failure to raise sufficient additional capital could lead to delaying, discontinuing certain clinical activities, or ceasing operations.
• The success of current or planned clinical trials is highly uncertain, including the ability to conduct and complete trials, achieve desired results, and obtain regulatory approvals.
• The possibility that products in development may fail clinical trials or not be approved by regulatory authorities.
• Material weaknesses identified in internal control over financial reporting, including an ineffective control environment and ineffective IT general controls, which could disrupt business on a longer-term basis.
• Dependence on third-party suppliers and manufacturers, with risks related to their performance and the ability to find alternative sources.
• Exposure to liability, litigation, or reputational damage related to data security.
• Dilution of existing stockholders' ownership interest if additional capital is raised through equity or debt financings.
• The valuation of private common warrants could increase volatility in net income (loss).

Future Outlook

The company plans to meet with the FDA in Q4-2025 to discuss submitting a New Drug Application (NDA) for brilaroxazine based on existing positive Phase 3 RECOVER-1, OLE, and Phase 2 REFRESH trial data, targeting an NDA submission in Q2-2026 if the FDA response is positive. A potential Phase 3 RECOVER-2 trial may be initiated in early 2026 if required by the FDA. The company expects to incur significant expenses and increased operating losses for the next several years as it advances product candidates and prepares for potential commercialization, requiring substantial additional capital beyond existing cash, particularly in Q1-2026.

Management Comments

• We believe that we have adequate cash on hand to cover anticipated outlays through the fourth quarter of 2025 but will need additional fundraising activities and cash on hand during the first quarter of fiscal year 2026.
• These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
• We believe we have successfully completed with positive results the two randomized double blind trials, as well as the safety, pharmacology and non-clinical studies typically required for NDA approval. We therefore are preparing to meet with FDA to gain alignment on our path to NDA submission, including a discussion of whether there is a need for a second phase 3 study (RECOVER-2).
• If FDA tells us we need to initiate a second phase 3 study, we intend to commence it in early 2026, subject to financing.
• We are committed to continuing to improve our internal control over financial reporting, and also our IT general controls.

Industry Context

Reviva Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on central nervous system (CNS), inflammatory, and cardiometabolic diseases. The successful completion of Phase 3 trials for brilaroxazine positions it closer to potential market entry for schizophrenia, a significant unmet medical need. The company's strategy of seeking FDA alignment for NDA submission based on existing data, potentially bypassing a second Phase 3 trial, could accelerate market access if successful, but also carries regulatory risk. The need for continuous capital raises is typical for clinical-stage biotechs, but the 'going concern' warning and Nasdaq delisting threats highlight significant financial and operational challenges that could impact its competitive standing and ability to advance its pipeline.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings and not aware of any pending or threatened claims.

Stakeholder Impact

• Shareholders face significant dilution from recent and future capital raises, risk of delisting from Nasdaq, and uncertainty regarding the company's ability to continue as a going concern. Potential upside from brilaroxazine's clinical progress and NDA submission.
• Employees may be impacted by cost-cutting measures if additional funding is not secured, and implications from internal control weaknesses.
• Future customers could benefit from new therapies if brilaroxazine receives regulatory approval.
• Creditors face increased risk due to the "going concern" warning and working capital deficit.
• Suppliers and vendors face potential risk of delayed payments or contract modifications if financial difficulties persist.

Next Steps

• Closeout of clinical sites globally and preparation of the RECOVER study report for the OLE trial.
• Meeting with the FDA in Q4-2025 to discuss NDA submission for brilaroxazine based on existing data.
• Target NDA submission for brilaroxazine in Q2-2026 if FDA response is positive.
• Potential initiation of a Phase 3 RECOVER-2 Trial in early 2026, if required by the FDA and subject to financing.
• Raise additional funds during Q1-2026 to cover anticipated operating outlays.
• Monitor common stock bid price and Market Value of Listed Securities (MVLS) to regain Nasdaq compliance, potentially considering a reverse stock split.
• Continue efforts to remediate material weaknesses in internal control over financial reporting, including engaging third-party consultants and realigning personnel.
• Evaluate the impact of the "One Big Beautiful Bill Act" on consolidated financial statements.
• Advance development of RP1208 for depression and obesity, subject to additional financing.

Key Dates

Recommendation

While the positive clinical trial data for brilaroxazine is a significant scientific achievement and the reduced net loss is a positive financial trend, the company faces critical financial and operational challenges. The "going concern" warning, substantial working capital deficit, and imminent Nasdaq delisting threats introduce high levels of uncertainty and risk. The recent capital raises provide some short-term liquidity but also resulted in significant dilution. Investors should monitor the outcome of the FDA meeting, the company's ability to secure further financing, and its progress in addressing Nasdaq compliance and internal control weaknesses before making further investment decisions. The potential for an accelerated NDA submission is a positive catalyst, but the financial risks are too substantial for a "buy" recommendation at this stage.

Keywords

Reviva Pharmaceuticals, RVPH, 10-Q, Quarterly Report, Biopharmaceutical, Clinical-stage, Brilaroxazine, RP5063, Schizophrenia, Phase 3 Trial, Open Label Extension, OLE Study, NDA Submission, FDA Meeting, Drug Development, CNS Diseases, Neuropsychiatric, Going Concern, Nasdaq Delisting, Capital Raise, ATM Offering, Public Offering, Warrants, Financial Results, Research and Development, Internal Controls, Risk Factors, Intellectual Property, RP1208, Depression, Obesity